Compare ELF & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELF | TWST |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.0B |
| IPO Year | 2016 | 2018 |
| Metric | ELF | TWST |
|---|---|---|
| Price | $52.25 | $70.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 8 |
| Target Price | ★ $111.88 | $46.88 |
| AVG Volume (30 Days) | ★ 3.8M | 1.4M |
| Earning Date | 05-27-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $1,636,472,000.00 | $376,572,000.00 |
| Revenue This Year | $23.87 | $18.91 |
| Revenue Next Year | $17.15 | $15.07 |
| P/E Ratio | $121.57 | ★ N/A |
| Revenue Growth | ★ 24.59 | 20.32 |
| 52 Week Low | $49.72 | $23.30 |
| 52 Week High | $150.99 | $71.04 |
| Indicator | ELF | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 37.76 | 68.30 |
| Support Level | $49.72 | $41.85 |
| Resistance Level | $96.30 | N/A |
| Average True Range (ATR) | 3.16 | 4.38 |
| MACD | 0.29 | 1.47 |
| Stochastic Oscillator | 22.70 | 94.40 |
e.l.f. Beauty Inc is a multi-brand beauty company that offers inclusive, accessible, clean, vegan, and cruelty-free cosmetics and skin care products. The Company's mission is to make beauty accessible to every eye, lip, face, and skin concern. The company offers cosmetic accessories for women, which include eyeliner, mascara, false eyelashes, lipstick, foundation for the face, moisturizer, cleanser, and other tools through its stores and e-commerce channels.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.